The protection of Intellectual Property in the Pharmaceuticals and Biotechnology industries is vital not only to the success of these companies, but to the innovations they bring to the world. Chief IP Counsel in the life sciences must understand the environment in which they are working, and adjust strategies accordingly when policy changes occur. By staying on top of the latest relevant rules and actively managing their IP portfolios, these executives can help their businesses maintain a competitive edge and continue to advance.
Consero’s 2015 Data Report for Chief IP Officers in the Pharmaceuticals and Biotechnology industries, developed in partnership with CDS Legal and CPA Global, was created in connection with Consero’s industry-specific Intellectual Property, an invitation-only event hosted in November 2014. The report below contains eleven questions designed to highlight the opportunities and challenges Chief IP Counsel face today. While the report was limited to 41 participants, the answers provide valuable insight into the perspectives of these senior IP executives.